Literature DB >> 31062835

Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018.

B Vellas1, L J Bain, J Touchon, P S Aisen.   

Abstract

The 2018 Clinical Trials on Alzheimer's Disease (CTAD) conference showcased recent successes and failures in trials of Alzheimer's disease treatments. More importantly, the conference provided opportunities for investigators to share what they have learned from those studies with the goal of designing future trials with a greater likelihood of success. Data from studies of novel and non-amyloid treatment approaches were also shared, including neuroprotective and regenerative strategies and those that target neuroinflammation and synaptic function. New tools to improve the efficiency and productivity of clinical trials were described, including biomarkers and machine learning algorithms for predictive modeling.

Entities:  

Keywords:  Alzheimer’s disease; clinical trials; predictive modeling; recruitment; therapeutics

Mesh:

Substances:

Year:  2019        PMID: 31062835     DOI: 10.14283/jpad.2019.11

Source DB:  PubMed          Journal:  J Prev Alzheimers Dis        ISSN: 2274-5807


  4 in total

Review 1.  Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease.

Authors:  Delphine Boche; Alexander Gerhard; Elena Rodriguez-Vieitez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-08       Impact factor: 9.236

2.  Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer's Disease.

Authors:  Charles F Murchison; Byron C Jaeger; Jeff M Szychowski; Gary R Cutter; Erik D Roberson; Richard E Kennedy
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

3.  Mail and Telephone Outreach from Electronic Health Records for Research Participation on Cognitive Health and Aging.

Authors:  K Pun; C W Zhu; M T Kinsella; M Sewell; H Grossman; J Neugroschl; C Li; A Ardolino; N Velasco; M Sano
Journal:  J Prev Alzheimers Dis       Date:  2021

Review 4.  Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.

Authors:  Steven S Plotkin; Neil R Cashman
Journal:  Neurobiol Dis       Date:  2020-07-16       Impact factor: 7.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.